Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Mots-C

Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1, Mitochondrial-derived peptide MOTS-c

Quick Stats
Studies 137
Trials 5
Unknown OBSERVATIONAL NCT04027712

Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes. The investigators plan to investigate the association of both biofactors with high on-clopidogrel platelet reactivity and cardiovascular mortality in type 2 diabetic patients with Coronary artery disease

Detailed Description

In type II diabetic patients with Coronary artery disease treated with clopidogrel and aspirin, the investigators plan to measure: i. maximum platelet aggregation to adenosine diphosphate (ADP) by Light Transmission Aggregometry (LTAmax), as a marker of on-clopidogrel treatment platelet reactivity ii. Malondialdehyde (MDA), as oxidative stress marker, Mitochondrial-derived peptide MOTS-c and b-amyloid. blood levels.

Primary Outcomes

Measure: mots-c predicts cardiovascular mortality in diabetic with coronary artery disease
TimeFrame: 2 year follow up
Description: mots-c concentration in Diabetic with coronary artery disease treated with acetyl-salicylic and clopidogrel predicts cardiovascular mortality
Measure: b amyloid predicts cardiovascular mortality in diabetic with coronary artery disease
TimeFrame: 2 year follow up
Description: b amyloid concentration in Diabetic with coronary artery disease treated with acetyl-salicylic and clopidogrel predicts cardiovascular mortality
Measure: b amyloid predicts cardiovascular mortality in diabetic with coronary artery
TimeFrame: 2 year follow up
Description: Resistance to clopidogrel as defined by Light Transmission Aggregometry in diabetic with coronary artery disease treated with acetyl-salicylic and clopidogrel predicts cardiovascular mortality.

Trial Information

NCT ID

NCT04027712

Status

Unknown

Study Type

OBSERVATIONAL

Sponsor

University of Athens

Last Updated

December 15, 2025